Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol
2. Osi 906
3. Osi-906
4. Osi906
1. 867160-71-2
2. Osi-906
3. Linsitinib(osi-906)
4. Osi906
5. Osi 906
6. Osi-906aa
7. Osi-906 (linsitinib)
8. Asp-7487
9. 3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol
10. 15a52gpt8t
11. Chembl1091644
12. Mmv676605
13. Cis-3-(8-amino-1-(2-phenyl-7-quinolinyl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol
14. (1r,3r)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol.
15. Linsitinib [usan]
16. Kinome_3532
17. Linsitinib [usan:inn]
18. Unii-15a52gpt8t
19. Cis-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutan-1-ol
20. Cis-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutan-1-ol
21. Linsitinib; Osi-906
22. Linsitinib [inn]
23. Linsitinib (usan/inn)
24. Linsitinib (osi-906)
25. Linsitinib [who-dd]
26. Mls006010304
27. Schembl400369
28. Schembl400734
29. Schembl400735
30. Gtpl7423
31. Chembl1996234
32. Schembl10255925
33. Chebi:91402
34. Ex-a719
35. Bcpp000137
36. Bdbm185150
37. Dtxsid401007055
38. Dtxsid901121553
39. Hms3295g15
40. Hms3654c19
41. Bcp01831
42. Bdbm50315887
43. Mfcd12912153
44. Nsc756652
45. Nsc800784
46. S1091
47. Zinc53239527
48. Akos024464740
49. Zinc100071817
50. Zinc113742575
51. Bcp9001035
52. Ccg-264815
53. Cs-0242
54. Db06075
55. Nsc-756652
56. Nsc-800784
57. Pb22643
58. Ncgc00250375-02
59. Ncgc00250375-03
60. Ncgc00250375-11
61. Ncgc00250375-14
62. Ac-26953
63. As-16999
64. Hy-10191
65. Smr004700744
66. Ft-0670821
67. Sw218150-2
68. D09925
69. Sr-05000022538
70. J-520074
71. Q6554803
72. Sr-05000022538-1
73. Brd-k07667918-001-01-3
74. Q27163260
75. 3-[8-amino-1-(2-phenyl-7-quinolinyl)-3-imidazo[1,5-a]pyrazinyl]-1-methyl-1-cyclobutanol
76. (1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol
77. 1356958-77-4
78. 3-(8-amino-1-(2-phenylquinolin-7-yl)-2,3-dihydroimidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol
79. 3-[8-amino-1-(2-phenyl-quinolin-7-yl)-imidazo[1,5-a]pyrazin-3-yl]-1-methyl-cyclobutanol
80. 867160-72-3
81. Cis-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol
82. Cyclobutanol, 3-(8-amino-1-(2-phenyl-7-quinolinyl)imidazo(1,5-a)pyrazin-3-yl)-1-methyl-, Cis-
83. Trans-3-[8-amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol
| Molecular Weight | 421.5 g/mol |
|---|---|
| Molecular Formula | C26H23N5O |
| XLogP3 | 4.2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 3 |
| Exact Mass | 421.19026037 g/mol |
| Monoisotopic Mass | 421.19026037 g/mol |
| Topological Polar Surface Area | 89.3 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 663 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.
In laboratory studies of 28 human tumor cell lines, OSI-906 reduced growth of 15 cell lines representative of colorectal, lung, breast, pancreatic, and pediatric tumors and in mouse models. OSI-906 was particularly effective against tumors that are highly IGF-dependent such as colorectal cancers. According to the researchers, OSI-906 not only slowed tumor growth in mice, but decreased the size of some pre-existing tumors.
IGF-1R stimulates proliferation, enables onogenic transformation, and suppresses apoptosis. Inhibitors of IGF-1R are expected to have broad utility in oncology since the over-expression of IGF-1R and/or its ligands or the down-regulation of ligand binding proteins occurs in numerous human malignancies including lung, colon, breast, prostate, brain and skin cancers. In addition, signaling through the IGF system has been implicated in protecting tumor cells from apoptosis induced by anti-cancer treatments such as cytotoxic agents and EGFR inhibitors.
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
86
PharmaCompass offers a list of Linsitinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Linsitinib manufacturer or Linsitinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Linsitinib manufacturer or Linsitinib supplier.
PharmaCompass also assists you with knowing the Linsitinib API Price utilized in the formulation of products. Linsitinib API Price is not always fixed or binding as the Linsitinib Price is obtained through a variety of data sources. The Linsitinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Linsitinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Linsitinib, including repackagers and relabelers. The FDA regulates Linsitinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Linsitinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Linsitinib supplier is an individual or a company that provides Linsitinib active pharmaceutical ingredient (API) or Linsitinib finished formulations upon request. The Linsitinib suppliers may include Linsitinib API manufacturers, exporters, distributors and traders.
Linsitinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Linsitinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Linsitinib GMP manufacturer or Linsitinib GMP API supplier for your needs.
A Linsitinib CoA (Certificate of Analysis) is a formal document that attests to Linsitinib's compliance with Linsitinib specifications and serves as a tool for batch-level quality control.
Linsitinib CoA mostly includes findings from lab analyses of a specific batch. For each Linsitinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Linsitinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Linsitinib EP), Linsitinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Linsitinib USP).
